Osteoporosis – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Osteoporosis – Drugs In Development, 2023’, provides an overview of the Osteoporosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Osteoporosis
- The report reviews pipeline therapeutics for Osteoporosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Osteoporosis therapeutics and enlists all their major and minor projects
- The report assesses Osteoporosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Osteoporosis
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Osteoporosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Osteoporosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Ablynx NVAclaris Therapeutics Inc
AdAlta Ltd
Addpharma Inc
Aerami Therapeutics Inc
Affilogic SAS
AgeX Therapeutics Inc
Airsea (Taizhou) Pharmaceutical Ltd
AlphaMab Co Ltd
Alvotech SA
Amgen Inc
Angitia Biopharmaceuticals
Aryogen Pharmed Co
Augusta University
Aurobindo Pharma Ltd
aVaxziPen Limited
Aveta Biomics Inc
Bainan Biotech ApS
Baiya Phytopharm Co Ltd
Beijing Health Guard Biotechnology Inc
Beijing Northland Biotech Co Ltd
Beryl Therapeutics Inc
Better Life Pharmaceuticals Inc
Biocon Ltd
Bone Biologics Corp
Carpe Vitae Pharmaceuticals Pty Ltd
Cellatoz Therapeutics Inc
Celltrion Inc
Central Drug Research Institute
China NT Pharma Group Co Ltd
ChoDang Pharm Co Ltd
Cinnagen Co
Citragen Pharmaceuticals Inc
CK Regeon Inc
Clayton Biotechnologies Inc
Clonz Biotech Pvt Ltd
Columbia University Medical Center
Corium Inc
CSPC Pharmaceutical Group Ltd
Curexsys GmbH
Daewoong Pharmaceutical Co Ltd
Dongkook Pharmaceutical Co Ltd
Eden Biologics Inc
Eli Lilly and Co
Endoceutics Inc
Entera Bio Ltd
Enteris BioPharma Inc
Enzene Biosciences Ltd
Enzo Biochem Inc
Epygen Biotech Pvt Ltd
Ewha Womans University
Fresenius Kabi SwissBioSim GmbH
Galapagos NV
Gedeon Richter Plc
Genor BioPharma Co Ltd
GENUONE Sciences Inc
GlycoNex Inc
GPN Therapeutics Inc
Haoma Medica Ltd
Helixmith Co Ltd
Histide AG
HK inno.N Corp
HNB Therapeutics LLC
Hualan Biological Engineering Inc
Huons Global Co Ltd
Icahn School of Medicine at Mount Sinai
Indiana University School of Medicine
InnoPharmaScreen Inc
Innopharmax Inc
iProgen Biotech Inc
Ipsen SA
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Pacific Meinuoke Bio-Pharmarceutical Co Ltd
Jiangsu T-mab BioPharma Co Ltd
Keros Therapeutics Inc
Kyoto Pharmaceutical Industries Ltd
Lactocore Inc
Lead Discovery Center GmbH
Lexeo Therapeutics Inc
Link Biologics Ltd
Lupin Ltd
Luye Pharma Group Ltd
Mabion SA
Mabxience Holding SL
Max Biopharma Inc
Max Delbruck Center for Molecular Medicine
Medispan
Merck & Co Inc
Mesentech Inc
Mezomax Inc
Minapharm Pharmaceuticals
Monash University
Nano Intelligent Biomedical Engineering Corp
Nanomedic Inc
NeuClone Pty Ltd
NextCure Inc
NovMetaPharma Co Ltd
Omeros Corp
Oncosimis Biotech Pvt Ltd
Ortho Regenics Pvt Ltd
Osaka University
OssiFi Inc
Paras Biopharmaceuticals Finland Oy
PhytoHealth Corp
Prestige BioPharma Ltd
PRG S&Tech Inc
Qualix DoT sl
Radius Health Inc
Rani Therapeutics LLC
Regenerative Arthritis & Bone Medicine Inc
Reliance Life Sciences Pvt Ltd
Saarland University
Samsung Bioepis Co Ltd
Sandoz Group AG
Shaanxi Micot Technology Co Ltd
Shandong New Time Pharmaceutical Co Ltd
Shanghai Braegen Pharmaceutical Co Ltd
Shanghai Celgen Bio-Pharmaceutical Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Junshi Biosciences Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Stony Brook University
Strides Pharma Science Ltd
Surrozen Inc
Suzhou Stainwei Biotech Inc
Taithera Inc
Takeda Pharmaceutical Co Ltd
Tempest Therapeutics Inc
Teva Pharmaceutical Industries Ltd
The National Institute for Biotechnology in the Negev Ltd
The Scripps Research Institute
The United Laboratories International Holdings Ltd
Transcenta Holding Ltd
Tritech Biopharmaceuticals Co Ltd
TSH Biopharm Corporation Ltd
Tulane University
Uni-Bio Science Group Ltd
Univeristy of Zaragoza
University of California San Diego
University of Hong Kong
University of Montpellier
University of Toledo
University of Wisconsin Madison
Vibe Pharmaceuticals LLC
Victoria University of Wellington
Vidasym Inc
Viking Therapeutics Inc
Wonkwang University
Wuxi Hebang Biotechnology Co Ltd
Yonsei University
Yooyoung Pharm Co Ltd
Zosano Pharma Corp
Zydus Lifesciences Ltd